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Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease characterized by
interstitial fibrosis and progressive respiratory failure. Pirfenidone and nintedanib slow down
but do not stop the progression of IPF. Thus, new compounds with high antifibrotic activity and
simultaneously regenerative activity are an unmet clinical need. Recently, we showed that Treamid can
help restoring the pancreas and testicular tissue in mice with metabolic disorders. We hypothesized
that Treamid may be effective in antifibrotic therapy and regeneration of damaged lung tissue
in pulmonary fibrosis. In this study, experiments were performed on male C57BL/6 mice with
bleomycin-induced pulmonary fibrosis. We applied histological and immunohistochemical methods,
ELISA, and assessed the expression of markers of endothelial and epithelial cells in primary cultures
of CD31+ and CD326+ lung cells. Finally, we evaluated esterase activity and apoptosis of lung cells
in vitro. Our data indicate that Treamid exhibits antifibrotic activity in mice with pulmonary fibrosis
and has a positive effect on capillaries of the lungs. Treamid also increases the number of endothelial
progenitor cells in the lungs of animals with pulmonary fibrosis. Lastly, Treamid increases esterase
activity and decreases apoptosis of CD31+ lung cells in vitro. Based on these findings, we suggest
that Treamid may represent a promising compound for the development of new antifibrotic agents,
which are capable of stimulating regeneration of lung endothelium in IPF patients.
Keywords: pulmonary fibrosis; Treamid; regeneration; endothelial progenitor cells
1. Introduction
According to respiratory societies, the problem of treating idiopathic pulmonary fibrosis (IPF) is
far from being solved [1,2]. Drugs widely used for the treatment of IPF (pirfenidone and nintedanib) do
not show sufficient antifibrotic activity. Moreover, they only slow down but do not stop the progression
of the disease [3] and are associated with severe side effects after long-term prescription [4–6]. The lack
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of effective treatment for IPF is aggravated by the fact that progressive pulmonary fibrosis is one of the
main and serious complications in patients who have undergone COVID-19 coronavirus infection [7,8].
IPF is associated with both a vascular injury and a repair defect. The mechanisms that underlie
these vascular abnormalities are still largely unknown. An important role of endothelial progenitor
cells in lung repair has been suggested in animal models and in the human system [9,10]. It is suggested
that endothelial cells may contribute to fibrosis in two ways: by becoming dysfunctional and by
differentiating into highly fibrogenic mesenchymal cells referred to as myofibroblasts [11]. Current
data suggest that the effect on endothelial dysfunction may potentially contribute to regeneration and
recovery of the damaged pulmonary endothelium at the pulmonary fibrosis [9].
New metal chelators have been identified as effective therapeutic agents in regeneration of organs
affected by diabetic degeneration [12–15]. Treamid (or bisamide derivative of dicarboxylic acid) is an
effective complexing agent, for which high logK1 ≥ 5 (5.50 and 5.24) values were found in relation to
transition metal ions [16]. Recently, we have shown that Treamid can chelate metal ions including zinc,
copper, iron, magnesium, and calcium [16,17]. Treamid has regenerative properties and restores the
function of various tissues and organs [16–18].
The aim of this study was to evaluate the antifibrotic and regenerative effects of Treamid in
C57BL/6 mice with bleomycin (BLM)-induced pulmonary fibrosis. In addition, we evaluated the effect
of Treamid on its potential cellular targets such as lung endothelial progenitor cells.
2. Results
2.1. The Effect of Treamid on Lungs Damaged by Bleomycin
2.1.1. Effects of Treamid on Tissue Morphology
Bleomycin, a chemotherapeutic agent, leads to interstitial lymphocytic inflammation, alveolar
epithelial cell injury, fibroblast proliferation, interstitial widening, and fibrosis. As an initial assessment,
histological analysis of hematoxylin and eosin (HE)-stained lung sections was performed to examine
whether the fibrotic response in mice receiving BLM was ameliorated by Treamid administration.
Histological data obtained on d8 of BLM administration showed that BLM caused interstitial and
interalveolar edema, hemorrhages, fibrin accumulation in the alveoli in group 2 mice compared to
group 1 mice (Supplementary Materials Figure S1). The interstitial inflammatory infiltrate in the
interalveolar septa consisted of lymphocytes, plasma cells, and macrophages. Fibrin thrombi of various
degrees of organization were found in the capillaries of the walls of the alveoli and in the small branches
of the pulmonary artery.
On 21st day (d21) after the BLM injection (the fibrotic phase of pulmonary fibrosis after BLM
treatment), infiltration of inflammatory cells (lymphocytes, macrophages) into the lung tissue was
observed in group 2 mice (mice with BLM) (Figure 1a,b).
The inflammatory response has been found to be predominantly perivascular and peribronchial.
In group 2 mice, fibrosis around the alveolar passages, collapse of the alveoli, an increase in the number
of alveolocytes, and thickening of the interalveolar septa were found. In some areas of the lungs,
restructuring of the lung tissue with the formation of a “honeycomb lung” was detected. In addition,
BLM caused thickening of the walls of the alveoli and vascular congestion in the lungs.
Treamid was administered at d14 to assess the effect of the compound on the fibrotic phase of BLM
model mice. Treamid reduced the density of lympho-macrophage infiltration of the lung parenchyma
and the thickness of the alveolar walls in group 3 mice with (pulmonary fibrosis treated with Treamid)
compared to mice in group 2 (d21). The treatment did not reveal vascular congestion and “honeycomb
lung” in group 3 (Figure 1c). Notably, the destruction of the alveoli was less pronounced than in the
untreated mice. Overall, administration of Treamid (10 mg/kg on d14–d20) ameliorated the lesions.
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Figure 1. Photomicrographs of left lung sections (middle pulmonary field) obtained from male 
C57BL/6 mice on 21st day after the BLM injection (d21). (a, d)  Mice of Intact control; (b, e) mice 
with pulmonary fibrosis; (c, f) mice with pulmonary fibrosis treated Treamid. (a–c) Tissues stained 
with hematoxylin-eosin; (d–f) tissues stained by Van Gieson, scale bar 100 μm. (g) Content of the 
connective tissue in the lungs of C57BL/6 mice at the pulmonary fibrosis on d21. (h) The mean linear 
intercept (Lm) in the lungs of male C57BL/6 mice with pulmonary fibrosis on d21 (upper, middle 
and lower pulmonary field). (i) Destructive index (DI) in the lungs of C57BL/6 mice with pulmonary 
fibrosis on d21 (upper, middle and lower pulmonary field). (j) The number of capillaries in five 
consecutive fields of lungs sections (upper, middle and lower pulmonary field) obtained from male 
C57BL/6 mice on d21. Groups: intact control; mice with pulmonary fibrosis (pulmonary fibrosis); 
mice with pulmonary fibrosis treated Treamid (pulmonary fibrosis+Treamid). * p < 0.05 significance 
of difference compared with intact control group, ● p < 0.05 significance of difference compared 
with the pulmonary fibrosis group. 
The inflammatory response has been found to be predominantly perivascular and 
peribronchial. In group 2 mice, fibrosis around the alveolar passages, collapse of the alveoli, an 
increase in the number of alveolocytes, and thickening of the interalveolar septa were found. In 
some areas of the lungs, restructuring of the lung tissue with the formation of a “honeycomb lung” 
was detected. In addition, BLM caused thickening of the walls of the alveoli and vascular congestion 
in the lungs. 
Treamid was administered at d14 to assess the effect of the compound on the fibrotic phase of 
BLM model mice. Treamid reduced the density of lympho-macrophage infiltration of the lung 
parenchyma and the thickness of the alveolar walls in group 3 mice with (pulmonary fibrosis treated 
with Treamid) compared to mice in group 2 (d21). The treatment did not reveal vascular congestion 
and “honeycomb lung” in group 3 (Figure 1c). Notably, the destruction of the alveoli was less 
pronounced than in the untreated mice. Overall, administration of Treamid (10 mg/kg on d14–d20) 
ameliorated the lesions. 
Figure 1. Photomicrographs of left lung sections (middle pulmonary field) obtained from male
C57BL/6 ice on 21st day after the BL injection (d21). (a,d) Mice of Intact control; (b,e) mice with
pulmonary fibrosis; (c,f) mice with pulmonary fibrosis treated Treamid. (a–c) Tissues stained with
hematoxylin-eosin; (d–f) tissues stained by Van Gieson, scale bar 100 µm. (g) Content of the connective
tissue in the lungs of C57BL/6 mice at the pulmonary fibrosis on d21. (h) The mean linear intercept (Lm)
i the lungs of male C57BL/6 mice with pulmonary fibrosis on d21 (upper, middle and lower pul onary
field). (i) Destructive index (DI) in the lungs of C57BL/6 mice with pulmonary fibrosis on d21 (upper,
middle a d lower pulmonary field). (j) The nu ber of capillaries in five consecutive fields of lungs
sections (upper, middle and lower pulmonary field) obtained f om ale C57BL/6 mice on 21. Groups:
intact control; mice with pulmonary fibrosis (pul onary fibrosis); mice with pulmonary fib osis t eated
Treamid ( l r fi +Treamid). * p < 0.05 significance of difference compared with intact
control group, • p < 0.05 significance of difference com ared with the pulmonary fib osis gr up.
2.1.2. Evaluation of Collagen Fibers
Van Gieson staining of lung preparations with picrofuchsin revealed deposition of collagen
fibers in the lungs of group 2 mice (p < 0.05) which was absent in group 1 mice (d21). Deposition of
collagen fibers was more profound adjacent to vessels and bronchioles (Figure 1e). Treamid reduced
(p < 0.05) the size of collagen deposition in the alveolar alls of group 3 mice compared to group 2
mice (Figure 1f). Moreover, treatment with Treamid led to a decrease in the thickness of the alveolar
septa and restoration of the airiness of the lung tissue.
2.1.3. Mean Linear Int rcept (Lm)
Mean linear intercept (Lm) measures are routinely used in the assessment of clinically relevant
lung pathology [19]. BLM significantly increased (p < 0.05) Lm in the upper, middle, and lower lung
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segments in group 2 mice compared to group 1 mice (d21) (Figure 1h). Treamid had no effect on Lm in
the middle and lower lungs of group 3 mice compared to group 2 mice. Finally, Treamid (10 mg/kg on
d14–d20) decreased (p < 0.05) Lm in the upper segment of the lungs (Figure 1h).
2.1.4. Destructive Index (DI)
The degree of morphologic changes in affected lung may be assessed by stratified random field
selection and subsequent qualitative morphometric and pathologic analysis, such as the DI [20].
Modeling of pulmonary fibrosis caused a significant increase (p < 0.05) of the DI in the upper, middle
and lower lung segments of group 2 mice compared to group 1 mice (d21) (Figure 1i). Treamid reduced
(p < 0.05) DI in all lung segments in group 3 mice compared to group 2 mice (Figure 1i).
2.1.5. Capillaries of the Lungs
Altered vascular architecture occurred predominantly in the subpleural and peribronchial regions
in BLM-treated mice, whereas the vehicle group showed intact lung architecture. BLM administration
reduced (p < 0.05) the number of capillaries in the lungs of group 2 mice compared to group 1 mice
(d21) (Figure 1j). Treamid caused a consistent trend towards an increase in the number of capillaries
in the upper and lower lungs of group 3 mice compared to group 2 mice (Figure 1j). Moreover,
the microvascular architecture in the lungs of Treamid-treated mice resembled normal, autochthonous
vascular lung architecture with alveolar plexus.
2.2. Effect of Treamid on the Molecules of Fibroblastic Process Expression in Bleomycin Damaged Lungs
In mice with pulmonary fibrosis, an increase of total collagen, type 1 collagen, hydroxyproline,
fibronectin, and connective tissue growth factor (p < 0.05) was observed in the lung homogenates of
group 2 mice compared to group 1 mice on d21 (Figure 2). After Treamid administration (10 mg/kg on
d14–d20), lower (p < 0.05) levels of total collagen, type 1 collagen, hydroxyproline, and fibronectin
were found in lung homogenates of group 3 mice than in group 2 mice (d21) (Figure 2). The treatment
did not affect connective tissue growth factor.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 19 
 
 
Figure 2. Effects of Treamid treatment on total soluble collagen (a), collagen type I (b), 
hydroxyproline (c), fibronectin (d), and connective tissue growth factor (e) levels in homogenate of 
right lung lobes received from male C57BL/6 mice (d21). Groups: intact control; mice with 
pulmonary fibrosis (pulmonary fibrosis); mice with pulmonary fibrosis treated Treamid (pulmonary 
fibrosis+Treamid). * p < 0.05 significance of difference compared with intact control group, ● p < 0.05 
significance of difference compared with the pulmonary fibrosis group. 
2.3. Effects of Treamid on IL-13 in Bleomycin Damaged Lungs 
IL-13 has been shown to contribute to inflammation and fibrosis in multiple animal models of 
pulmonary fibrosis including bleomycin-induced pulmonary fibrosis [21]. Pulmonary fibrosis 
caused an increase in the level of IL-13 in the lung homogenate of group 2 mice compared to group 1 
mice (d21) (Supplementary Materials Figure S2). After Treamid administration, significantly lower 
(p < 0.05) levels of IL-13 were found in lung homogenates of group 3 mice compared to group 2 mice 
(Supplementary Materials Figure S2). 
2.4. Effects of Treamid on Lung Endothelial Progenitor Cells In Vivo 
To identify the mechanism underlying the antifibrotic and regenerative effects of Treamid, flow 
cytometry was used to measure the number of lung endothelial progenitor cells in the lung tissue. 
Pulmonary fibrosis decreased (p < 0.05) the number of hemangiogenesis precursors 
(CD45-CD117+CD309+), endothelial progenitor cells (CD45-CD31+CD34+) VEGF2+ endothelial cells 
(CD309+CD45-), epithelial cells (CD45-Ter119-CD326+), and Clara cells (CD45-CD34-CD31-Sca1+) in 
the lungs of group 2 mice compared to group 1 mice (d21) (Figure 3, Supplementary Materials 
Figure S3). In addition, there was a tendency towards a decrease in the number of epithelial 
progenitor cells (CD45-CD117+CD49f+) (0.460 ± 0.044—control and 0.400 ± 0.005—mice with 
pulmonary fibrosis). Treamid administration caused a significant increase (p < 0.05) in the number of 
hemangiogenesis precursors, endothelial progenitor cells, and VEGF2+ endothelial cells in the lungs 
of group 3 mice compared to group 2 mice (Figure 3). Treamid increased (p < 0.05) the number of 
Clara cells in the lungs but had no effect on epithelial progenitor cells. 
Figure 2. Effects of Treamid treatment on total soluble collagen (a), collagen type I (b), hydroxyproline
(c), fibronectin (d), and connective tissue growth factor (e) levels in homogenate of right lung lobes
received from male C57BL/6 mice (d21). Groups: intact control; mice with pulmonary fibrosis
(pulmonary fibrosis); mice with pulmonary fibrosis treated Treamid (pulmonary fibrosis+Treamid).
* p < 0.05 significance of difference compared with intact control group, • p < 0.05 significance of
difference compared with the pulmonary fibrosis group.
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2.3. Effects of Treamid on IL-13 in Bleomycin Damaged Lungs
IL-13 has been shown to contribute to inflammation and fibrosis in multiple animal models
of pulmonary fibrosis including bleomycin-induced pulmonary fibrosis [21]. Pulmonary fibrosis
caused an increase in the level of IL-13 in the lung homogenate of group 2 mice compared to group 1
mice (d21) (Supplementary Materials Figure S2). After Treamid administration, significantly lower
(p < 0.05) levels of IL-13 were found in lung homogenates of group 3 mice compared to group 2 mice
(Supplementary Materials Figure S2).
2.4. Effects of Treamid on Lung Endothelial Progenitor Cells In Vivo
To identify the mechanism underlying the antifibrotic and regenerative effects of Treamid,
flow cytometry was used to measure the number of lung endothelial progenitor cells in the
lung tissue. Pulmonary fibrosis decreased (p < 0.05) the number of hemangiogenesis precursors
(CD45−CD117+CD309+), endothelial progenitor cells (CD45−CD31+CD34+) VEGF2+ endothelial cells
(CD309+CD45−), epithelial cells (CD45−Ter119−CD326+), and Clara cells (CD45−CD34−CD31−Sca1+)
in the lungs of group 2 mice compared to group 1 mice (d21) (Figure 3, Supplementary Materials
Figure S3). In addition, there was a tendency towards a decrease in the number of epithelial progenitor
cells (CD45−CD117+CD49f+) (0.460 ± 0.044—control and 0.400 ± 0.005—mice with pulmonary fibrosis).
Treamid administration caused a significant increase (p < 0.05) in the number of hemangiogenesis
precursors, endothelial progenitor cells, and VEGF2+ endothelial cells in the lungs of group 3 mice
compared to group 2 mice (Figure 3). Treamid increased (p < 0.05) the number of Clara cells in the
lungs but had no effect on epithelial progenitor cells.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 19 
 
 
Figure 3. Characterization of CD45-СD117+CD309+, CD309+CD45-, CD45-CD31+CD34+ endothelial cell 
population isolated from lung of male C57BL/6 mice on d21. Cells were analyzed by flow cytometry 
using antibodies for mouse CD45, CD31, CD34, CD117, CD309. Dot plots are representative for 
three independent experiments with the mean from three independent experiments. (a) The content 
of angiogenesis progenitors (CD45-CD117+CD309+) in the lung of mice. (b) The content of 
endothelial cells (CD309+CD45-) in the lung of mice. (c) The content of endothelial progenitor cells 
with phenotype CD45-CD31+CD34+ in the lung of mice. Groups: control, pulmonary fibrosis and 
pulmonary fibrosis treated by Treamid. * Significance of difference compared with intact control (p < 
0.05); ● significance of difference compared with the pulmonary fibrosis group (p < 0.05). (d) Isotype 
control for IgG2a (PerCP). (e) Phenotype establishment and qualitative analysis of CD45 (PerCP). (f) 
Phenotype establishment and qualitative analysis of CD34 (FITC), CD31 (APC). (g) Isotype control 
for IgG2a (PerCP). (h) Isotype control for IgG2b (APC). (i) Phenotype establishment and qualitative 
analysis of CD309 (APC) expression. (j) Isotype control for IgG2b (PE-Cy7) and for IgG2b (APC). (k) 
Phenotype establishment and qualitative analysis of CD117 and CD309 (APC) expression. 
2.5. The Effect of Treamid on CD31+ Cells In Vitro 
Angiogenesis is a physiological process that maintains organ homeostasis. In contrast, 
dysregulated neovascularization is involved in pathological conditions such as pulmonary fibrosis. 
We observed an increase in the number of apoptotic CD31+ cells in culture of cells isolated from mice 
with pulmonary fibrosis compared to cells isolated from group 1 mice (Figure 4b). The effects of 
Treamid on CD31+ cells were studied on cells isolated from lungs of groups 1 and 3. We found that 
Treamid significantly reduced the number of apoptotic CD31+ cells in group 3 (Figure 4b, 3.9 times p 
< 0.05) but had no significant effects on the number of apoptotic CD31 + cells in group 1. Treamid 
increased the number of CD31+ cells with active esterases in group 3 (by 58% compared to control 
culture, p < 0.05) (Figure 4a). A similar effect was observed in group 1. 
Figure 3. Characterization of CD45−CD117+CD309+, CD309+CD45−, CD45−CD31+CD34+ endothelial
cell population isolated from lung of male C57BL/6 mice on d21. Cells were analyzed by flow cytometry
using antibodies for mouse CD45, CD31, CD34, CD117, CD309. Dot plots are representative for three
independent experiments with the mean from three independent experiments. (a) The content of
angiogenesis progenitors (CD45−CD117+CD309+) in the lung of mice. (b) The content of endothelial
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cells (CD309+CD45−) in the lung of mice. (c) The content of endothelial progenitor cells with phenotype
CD45−CD31+CD34+ in the lung of mice. Groups: control, pulmonary fibrosis and pulmonary
fibrosis treated by Treamid. * Significance of difference compared with intact control (p < 0.05);
• significance of difference compared with the pulmonary fibrosis group (p < 0.05). (d) Isotype control
for IgG2a (PerCP). (e) Phenotype establishment and qualitative analysis of CD45 (PerCP). (f) Phenotype
establishment and qualitative analysis of CD34 (FITC), CD31 (APC). (g) Isotype control for IgG2a
(PerCP). (h) Isotype control for IgG2b (APC). (i) Phenotype establishment and qualitative analysis of
CD309 (APC) expression. (j) Isotype control for IgG2b (PE-Cy7) and for IgG2b (APC). (k) Phenotype
establishment and qualitative analysis of CD117 and CD309 (APC) expression.
2.5. The Effect of Treamid on CD31+ Cells In Vitro
Angiogenesis is a physiological process that maintains organ homeostasis. In contrast,
dysregulated neovascularization is involved in pathological conditions such as pulmonary fibrosis. We
observed an increase in the number of apoptotic CD31+ cells in culture of cells isolated from mice with
pulmonary fibrosis compared to cells isolated from group 1 mice (Figure 4b). The effects of Treamid
on CD31+ cells were studied on cells isolated from lungs of groups 1 and 3. We found that Treamid
significantly reduced the number of apoptotic CD31+ cells in group 3 (Figure 4b, 3.9 times p < 0.05) but
had no significant effects on the number of apoptotic CD31 + cells in group 1. Treamid increased the
number of CD31+ cells with active esterases in group 3 (by 58% compared to control culture, p < 0.05)
(Figure 4a). A similar effect was observed in group 1.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 19 
 
 
Figure 4. Effects of Treamid on culture of CD31+ endothelial cells isolated from the lungs of male 
C57BL/6 mice. (a) The level of carboxyfluorescein succinimidyl ester (CFSE) activity and (b) the 
count of apoptotic CD31+ cells after culture with or without Treamid (10−7 М). All data are expressed 
as mean±SD, * significance of difference compared with control (p < 0.05); ● significance of 
difference compared without Treamid group (p < 0.05). (c) CD31+ endothelial cells were precultured 
for five days, and incubated with or without Treamid (10−7 M) for 1 h; (d) culture of CD31+ 
endothelial cells from lung were precultured for 5 days, and incubated with or without Treamid 
(10−7 M) for 1 h and then labeled with Hoechst and CFSE (FITC) prior to fluorescence microscopic 
analysis. Images (20×) of CD31+ cells stained with: Hoechst (blue) to identify cell nuclei; CFSE 
(green); (Hoechst + CFSE) composite image using all two colors. Determination of the percentage of 
cells with CFSE activity was made as a ratio of cells counted in the green channel to total positive 
cells. All scale bars are 100 μm. 
3. Discussion 
IPF is a chronic progressive disease characterized by a development of interstitial fibrosis, and 
progressive respiratory failure [22,23]. In most cases, the prognosis of IPF is unfavorable, with a life 
expectancy of five years after diagnosis [24,25]. Risk factors that can precipitate the development of 
fibrotic disease are hereditary factors, repeated exposure to toxins, smoking, chronic autoimmune 
inflammation, myocardial infarction, high serum cholesterol, obesity, diabetic disorders, and 
hypertension [23,26]. In addition, inflammation can be significant in the initiation and progression of 
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C57BL/6 mice. (a) The level of carboxyfluorescein succinimidyl ester (CFSE) activity and (b) the count
of apoptotic CD31+ cells after culture with or without Treamid (10−7 M). All data are expressed as
mean±SD, * significance of difference compared with control (p < 0.05); • significance of difference
compared without Treamid group (p < 0.05). (c) CD31+ endothelial cells were precultured for five
days, and incubated with or without Treamid (10−7 M) for 1 h; (d) culture of CD31+ endothelial cells
from lung were precultured for 5 days, and incubated with or without Treamid (10−7 M) for 1 h and
then labeled with Hoechst and CFSE (FITC) prior to fluorescence microscopic analysis. Images (20×)
of CD31+ cells stained with: Hoechst (blue) to identify cell nuclei; CFSE (green); (Hoechst + CFSE)
composite image using all two colors. Determination of the percentage of cells with CFSE activity was
made as a ratio of cells counted in the green channel to total positive cells. All scale bars are 100 µm.
3. Discussion
IPF is a chronic progressive disease characterized by a development of interstitial fibrosis,
and progressive respiratory failure [22,23]. In most cases, the prognosis of IPF is unfavorable,
with a life expectancy of five years after diagnosis [24,25]. Risk factors that can precipitate the
development of fibrotic disease are hereditary factors, repeated exposure to toxins, smoking, chronic
autoimmune inflammation, myocardial infarction, high serum cholesterol, obesity, diabetic disorders,
and hypertension [23,26]. In addition, inflammation can be significant in the initiation and progression
of fibrosis [27,28]. Generally, chronic inflammation, which lasts for months or years, precedes the
nascence of IPF.
In IPF, the main cellular targets are alveolar epithelial cells. In this study, we demonstrated that
BLM disrupts the integrity of the alveoli and damages alveolar epithelial cells (Figure 1, Supplementary
Materials Figure S4). Moreover, we observed an increase in the numbers of mature epithelial cells
(CD45−Ter119−CD326+) and epithelial progenitor cells (CD45−Ter119−CD49f+) in lungs of mice of
group 2 (Supplementary Materials Figure S3). This discrepancy between the in vitro and in vivo
experiments could be explained by inhibitory effects of inflammation on epithelial cells. The cells
that contribute to this phenomenon might by interstitial macrophages migrating into the lungs after
BLM administration (Supplementary Materials Figure S5). This is in general accordance with previous
studies showing a recruitment of interstitial macrophages from the circulation into the lungs in response
to acute lung injury [21,23].
Various independent research groups have shown that in pulmonary fibrosis, damaged cells of the
alveolar epithelium are able to induce the migration, proliferation and activation of mesenchymal cells,
which are involved in the fibroplastic process [27–29]. In this study, we have found an accumulation
of MSCs (CD45-CD31-CD34-CD73+CD90+) in the lungs of mice treated with BLM (Supplementary
Materials Figure S6). In this population of MSCs, the proportion of cells expressing Notch1 significantly
increased (Supplementary Materials Figure S6). In addition to these changes, group 2 mice showed
an accumulation of fibroblasts in the lungs and the formation of fibroblasts foci (Figure 1). Using
ELISA, we demonstrated upregulation of total collagen, type 1 collagen, hydroxyproline, fibronectin,
and connective tissue growth factor in lung homogenates from group 2 (Figure 2). Moreover, we were
able to show deposition of collagen fibers which might be a result of an activation of the fibroplastic
process. Notably, this process was most intense around the vessels and bronchioles.
The endothelium plays a central role in pulmonary vascular regulation and endothelial dysfunction
and is increasingly viewed as pivotal for initiation and progression of IPF [30]. In IPF, a pathological
vascular remodeling is observed [9,10,31,32]. Loss of the normal structure and function of the
endothelium during the destruction of epithelial cells can irreversibly lead to the loss of alveolar-capillary
integrity, after which the progression of fibrosis is difficult to stop. In areas of the lungs with fibrosis,
we found few or no blood vessels compared to healthy lungs, and a decreased CD31 expression in the
alveoli (Figure 1, Supplementary Materials Figure S7). In the lung tissue of mice with pulmonary fibrosis,
we found a significant decrease in the number of endothelial progenitor cells (CD45−CD31+CD34+),
VEGF2+ cells (CD309+CD45−), and hemangiogenesis precursors (CD45−CD117+CD309+) (Figure 3).
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At the same time, CD31+ cells of group 2 had a decreased esterase activity and increased frequency of
apoptosis compared to group 1 in vitro (Figure 4).
After treatment with Treamid, we observed a decrease in lung inflammation in group 3 mice
compared to group 2 mice as evidenced by a decrease in the density of lympho-macrophage infiltration
of the lung parenchyma (Figure 1), and a decrease in CD16 expression in the interstitium and
lung parenchyma (Supplementary Materials Figure S7). Cytometric analysis revealed a reduction
in the number of mononuclear phagocytes of various phenotypes in the lungs: CD11b+ (total
population of mononuclear phagocytes), CD45+CD19−Sca1+CD11b−F4/80+ (alveolar macrophages),
CD45+CD90+CD44+ (circulating monocytes and lymphocytes) (Supplementary Materials Figure S8).
As IL-13 is well-known, to induce respiratory disease [21,33,34], the decrease of the IL-13 concentration
in the lung homogenate in group 3 mice (Supplementary Materials Figure S2) might represent an
additional mechanistic aspect of the regenerative effects of Treamid. IL-13 is known to activate
fibroblasts that participate in the production and deposition of excess collagen and fibronectin in the
lungs and other organs [21]. However, anti-IL-13 clinical trials were stopped due to lack of efficacy
and could not meet their primary end points. This suggests that targeting the IL-13 alone may not be
beneficial in IPF.
Treamid reduced collagen deposition in the alveolar walls of group 3 mice compared to group
2 mice. This could be explained by the anti-inflammatory effects of Treamid. In contrast to group 2
mice, “honeycomb lungs” were not found in the treated mice. In addition, Treamid might interfere
with collagen production. This hypothesis is supported by much lower levels of total collagen, type 1
collagen, hydroxyproline and fibronectin in group 3 mice than in group 2 mice (Figure 2).
Treamid-mediated reduction of the inflammation and fibrosis had positive effects on the condition
of the alveoli. We found a decrease in alveolar destruction and a decrease in their wall thickness
in the treated mice. This led to the restoration of the alveoli structure of the lung tissue. However,
from our point of view, the most important effect of Treamid is the observed improvement of the lung
microvasculature. Lungs of group 3 mice did not reveal vascular congestion similar to that in group
2 (Figure 1). Moreover, Treamid caused an increase in the number of capillaries in the upper and
lower lungs (Figure 1), and an increased expression of VEGF2 (Figure 3). Our findings suggest that
pulmonary fibrogenesis and angiogenesis interact in the progression of pulmonary fibrosis. Treamid
might interfere with these pivotal pathogenetic mechanisms in pulmonary fibrosis, significantly
improving lung function and normalizing the microvascular architecture.
Overall, the beneficial effects of Treamid could be explained by its action on precursors of
endothelial cells. As shown in Figure 3, Treamid significantly increased the number of hemangiogenesis
precursors (CD45−CD117+CD309+), endothelial progenitor cells (CD45−CD31+ CD34+), and VEGF2+
endothelial cells in the lungs of group 3 mice compared to group 2 mice. In vitro, Treamid had no
significant effect on CD31+ lung cells from group 1 mice (Figure 4). In contrast, Treamid decreased the
number of apoptotic cells and increased the number of cells with active esterases in the culture of CD31+
lung cells from group of mice with pulmonary fibrosis (Figure 4). Thus, we associate the revealed
regenerative effect of Treamid on the pulmonary fibrosis model with the precursors of endothelial cells
with CD31+ being potential cellular targets. These findings are supported by the fact that Treamid
does not affect Clara cells and epithelial progenitor cells (CD45−CD117+CD49f+) in vivo and in vitro
(Supplementary Materials Figures S3 and S4).
4. Materials and Methods
4.1. Animals
Nine-week-old male C57BL/6 mice (Surgical Bio-modelling Department of the Goldberg ED
Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia) were used in all
experiments. Animals were randomly assigned into the experimental groups. All experimental
protocols were approved by the animal care and use committee of the Goldberg ED Research Institute
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of Pharmacology and Regenerative Medicine, Tomsk NRMC (IACUC Protocol No. 71052014, 30.09.2016).
Within this study, 60 mice were used.
4.2. Modeling of Experimental Pulmonary Fibrosis
Experimental pulmonary fibrosis was induced by a single intratracheal bleomycin (BLM, Nippon
Kayaku Co., Ltd., Tokyo, Japan) administration at a dose 80 µg/mouse in 0.03 mL of 0.9% NaCl, which
was slowly instilled in the tracheal lumen [35]. All procedures were performed under anesthesia
induced by intraperitoneal injection of chloral hydrate (400 mg/kg intraperitoneal). These animals
formed the BLM control. Control animals were administered a single intratracheal 0.03 mL 0.9% NaCl.
The introduction of BLM was defined as day zero (d0). All mice were euthanized on d21 by CO2.
Mice were cohoused (five to six mice per cage) and entrained to a reverse 12 h light/12 h dark
cycle. Throughout the experimental period, mice had ad libitum access to standard rodent chow.
4.3. Treamid
Treamid (bisamide derivative of dicarboxylic acid (BDDA), also known as XC268BG), chemical
formula N1,N5-bis [2-(1H-imidazole-2-Il)ethyl] glutaramide, was provided by the General Director of
the “PHARMENTERPRISES” Ltd. Mr. V. Nebolsin (Figure 5) [16–18].Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 10 of 19 
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4.4. Experimental Groups
Animals were allocated into three groups (n = 20/group): intact control (mice without BLM
receiving saline solution formed the control group—group 1), pulmonary fibrosis (mice with
BLM—group 2), and pulmonary fibrosis + Treamid (group 3—pulmonary fibrosis with Treamid
treatment).
Direct effects of Treamid on endothelial cells and epithelial cells were investigated in cultivated
mononuclear cells isolated from healthy mice and mice with pulmonary fibrosis on d21 (Figure 6).
For the in vitro experiments using CD31+ cells, four experimental groups were used: group
1—control (CD31+cells isolated from intact mice after culture), group 2—intact control + Treamid
(CD31+cells isolated from intact mice after culture + Treamid (10−7 M) for 1 h), group 3—pulmonary
fibrosis (CD31+ cells isolated from mice with pulmonary fibrosis after culture), group 4—pulmonary
fibrosis + Treamid (CD31+ cells isolated from mice with pulmonary fibrosis after culture + Treamid
(10−7 M) for 1 h) (Figure 6).
For the in vitro experiments using CD326+ cells, the following experimental groups were used:
group 1—control (CD326+cells isolated from intact mice after culture), group 2—intact control + Treamid
(CD326+ cells isolated from intact mice after culture + Treamid (10−7 M) for 1 h), group 3—pulmonary
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fibrosis (CD326+ cells isolated from mice with pulmonary fibrosis after culture), group 4—pulmonary
fibrosis + Treamid (CD326+ cells isolated from mice with pulmonary fibrosis after culture + Treamid
(10−7 M) for 1 h) (Figure 6).
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4.5. Enzyme-Linked Immunosorbent Assay
4.5.1. Hydroxyproline, Collagen Type I, Fibronectin, and Connective Tissue Growth Factor Measurements
Hydroxypro ine and collagen type I, fibronectin, and connective tissue growth factor (CTGF)
we e quantified n homogenate of right lung lobes. Hydroxyproline, collagen type I, fib onectin, an
CTGF were determined by ELISA according to manufacturer instructions (Cusabio Biotech CO., Ltd.,
Wuhan, China). The right lung lobes were excis d and snap frozen after having measured the wet
weight. Sensitivities were >1.95 ng/mL for hydroxyproline and CTGF, >0.039 ng/mL for collagen ype I,
>0.78 ng/mL for fibronectin.
4.5.2. Total Soluble Collagen Assay
Total soluble collagen was quantified in homogenate of right lung lobes. The right lung lobes
homogenate supernatants were placed in 1.5 mL tubes. Sircol-dye was added, the content of the
tubes homogenized for 30 min and centrifuged for 10 min (10.000× g). Pellets were dissolved with
alkaline reagent. Absorbance was read at 540 nm. The total soluble collagen was determined using
a standard curve for the SircolTM assay (S1000, Biocolor Ltd., Country Antrim, UK) according to
the manufacturer’s instructions. Results were expressed as mg collagen per right lung. Detection
limit: 1.0 µg.
4.5.3. Interleukin 13 Measurements
Interleukin 13 was measured in lung homogenates using specific ELISA kit from Cusabio according
to manufacturer instruction (Cusabio Biotech CO., Ltd., Wuhan, China). The right lung lobes were
excised and snap frozen after having measured the wet weight. Sensitivity was >7.8 ng/mL.
4.6. Histological Examination of Lung Tissue
The morphological examination of lungs was performed on d21. For histological studies, left lung
lobes were fixed in 4% neutral formalin solution, embedded in paraffin and sections with thickness of
5 µm were prepared. Subsequently, sections were staining with hematoxylin and eosin. Histological
examination was carried out in three areas of lung tissue (upper, middle and lower) on d21 as
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described previously [36]. Lung structure, presence of edema, infiltration by proinflammatory cells
as well as venous hyperemia, and vascular and bronchial walls thickening were assessed [37–39].
Micropreparations from each experimental animal were examined under the light microscope Axio
Lab.A1 (Carl Zeiss, MicroImaging GmbH; Göttingen, Germany) at 100× and 400×magnifications.
The degree of alveolar septa destruction was determined by measuring the destructive index (DI),
and increase of alveolar spaces was determined by calculating average linear interception Lm. Mean
linear intercept (MLI or Lm) is a measure of morphometric change based on serial measurements of
the lung using test lines but cannot be directly interpreted as a measure of alveolar size. MLI can be
most directly interpreted as the mean free distance between gas exchange surfaces in the acinar airway
complex [19]. Importantly, the use of Lm in the estimation of the structural substrate of lung function
is only applicable when considered a function of the total volume and surface area of the lung due to
the lung’s structural complexity and complex inflationary behavior. Lm calculation was performed
using FIJI and a 500 × 500 µm grid (10 horizontal and 10 vertical equally spaced lines) was placed in a
micrograph of a histological section lightly stained with hematoxylin-eosin. Lm was calculated using
the formula [40–42]:
Lm = (N × L)/m
where N is the number of lines placed on the tissue, L is the length of one line, m is the sum of
all intersections.
Pulmonary parenchyma destruction degree was determined as DI [43]. Briefly, a grid consisting
of 50 points with an area of 500 × 500 µm was placed on a microphotograph of a lung tissue using a
FIJI. The structures underlying these points were classified as normal or destroyed alveolar spaces
or airways. The points falling onto the other structures such as the airways or alveoli walls were not
considered. DI was calculated using the formula [43]:
DI = (D/(D + N)) × 100
Structures lying under these points were classified as normal (N) or destroyed (D) alveolar and/or duct
spaces. Points falling over other structures, such as duct walls, alveolar walls, etc., were not considered.
Micropreparations from each experimental animal were stained with hematoxylin and eosin were
examined under an Axio Lab.A1 microscope (Carl Zeiss, MicroImaging GmbH, Göttingen, Germany) at
2500-fold magnification using immersion microscopy to assess the microvasculature state. The number
of capillaries in five consecutive fields of view was calculated for each section [42,44].
To count collagen fibers in lung parenchyma, the histological slides were stained by picrofuchsin
using Van Gieson method [45,46]. At least 10 photomicrographs without overlapping across the cut
surface of the lung tissue at 100 x magnification were taken for each experimental animal. The used
system consisted of a microscope (Axio Lab.A1, Carl Zeiss MicroImaging GmbH; Göttingen, Germany)
with a video camera (AxioCam ERc5s, Carl Zeiss; Göttingen, Germany), connected to a personal
computer. Gathered images were processed using the software AxioVision Rel.4.8.2. The content of
collagen fibers in lung was determined using a function for counting the area of the object in the image.
Bronchovascular strands were carefully removed from the analyzed areas. To count collagen fibers
was calculated using the formula:
X = Σ a × 100/(S - Σ b)
where
∑
a is the sum of the pixels occupied by tissue with fibrosis in 10 images of one specimen, S is
the number of pixels corresponding to the full area of the image (when using this camera and the
program—4423680), b is the sum of pixels occupied by the empty part of the slide, in 10 images one
drug [45,46].
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4.7. Flow Cytometric Analysis
Mononuclear cells from lungs were isolated as described earlier [47,48] and the expression of
surface markers on mononuclear cells derived from lungs was analyzed. Fc-receptors were blocked
by preincubation of the cells with unconjugated anti-CD16/CD32 antibodies for 10 min (eBioscience,
San Diego, CA, USA, Clone: 93, Cat# 14-0161-85, 1/50 dilution) in 50 µL of 0.1% saponin (Sigma-Aldrich,
St. Louis, MO, USA, Cat# S4521) and 1% BSA (Sigma-Aldrich, St. Louis, MO, USA, Cat# A3059-100G)
in phosphate buffered saline (PBS) per tube. After the preincubation, cells suspensions were stained
with fluorophore-conjugated monoclonal antibodies: CD45 PerCP (QC Testing: Mouse, Clone: 30-F11,
Cat# 557235, 1/100 dilution) or CD45 APC-Cy 7 (QC Testing: Mouse, Clone: 30-F11, Cat# 557659,
1/100 dilution), CD31 APC (QC Testing: Mouse, Clone: MEC 13.3, Cat# 551262, 1/50 dilution), CD34
FITC (QC Testing: Mouse, Clone: RAM34, Cat# 560238, 1/50 dilution), CD309 (Flk-1) APC (QC Testing:
Mouse, Clone: Avas 12alpha1, Cat# 560070, 1/50 dilution), CD117 PeCy7(QC Testing: Mouse, Clone:
2B8, Cat# 558163, 1/50 dilution), Sca1 Per-Cy5.5 (QC Testing: Mouse, Clone: D7, Cat# 561021, 1/50),
CD73 V450 (QC Testing: Mouse, Clone: TY/23, Cat# 561544, 1/50), CD44 APC (QC Testing: Mouse,
Clone: IM7, Cat# 559250, 1/50), CD90 PerCP (QC Testing: Mouse, Clone: OX-7, Cat# 557266, 1/50),
CD44 APC (QC Testing: Mouse, Clone: IM7, Cat# 559250, 1/50), TER119 APC-Cy 7 (QC Testing:
Mouse, Clone: TER-119, Cat# 560509, 1/100), CD19 FITC (QC Testing: Mouse, Clone: D3, Cat# 553785,
1/50), CD11b Alexa Fluor® 647 (QC Testing: Mouse, Clone: M1/70, Cat# 557686, 1/50), F4/80 BV421
(QC Testing: Mouse, Clone: T45-2342, Cat# 565411, 1/50), Notch1 PE (QC Testing: Mouse, Clone:
mN1A, Cat# 552768, 1/50 dilution) (all Becton Dickinson, San Jose, CA, USA), and CD326 (EpCam) PE
(QC Testing: Mouse, Clone: caa7-9G8, Cat# 130-102-265, 1/50 dilution, Miltenyi Biotec B.V. & Co. KG,
Bergisch Gladbach, Germany). The antibody rat antihuman CD49f FITC (Clone: GoH3, Cat# 555735,
1/50, Becton Dickinson, San Jose, CA, USA) was rat antihuman with reactivity for mouse. All antibodies
were titrated to determine their optimal staining concentration and appropriate isotype controls
were used. Labeled cells were washed thoroughly with 500 µL of FACSFlow (Becton Dickenson,
Franklin Lakes, NJ, USA, Cat# 342003).
For the intracellular staining of the Notch1, a Fixation/Permeabilization Solution Kit (Becton
Dickinson, San Jose, CA, USA, Cat# 554714) was used in accordance with the manufacturer’s instructions.
After cell fixation and permeabilization, the BD Perm/Wash™ Buffer was used to wash the cells and to
dilute the Notch1 antibodies for staining.
All samples were run on a Becton Dickenson FACSCanto II flow cytometer. The instrument was
set up and standardized using BD Cytometer Setup and Tracking (CS&T) procedures according to
manufacturer specifications. One hundred thousand events per tube were acquired. Data were analyzed
using FACSDiva 8.0 software.
4.8. Lung Tissue Dissociation, Isolation and Magnetic Separation of CD31+ Lung Endothelial Cells
On d21 we studied the effect of Treamid on CD31+ lung endothelial cells of mice of the control
group (group 1) and mice with pulmonary fibrosis (group 2) in vitro. Lung endothelial cells were
isolated using protocol [47–49].
All metal instruments were sterilized by autoclaving; sterile disposables were from BD Falcon.
Lungs were isolated from surrounding tissue, rinsed with PBS (Sigma-Aldrich, St. Louis, MO, USA),
mechanically dispersed, and minced with scissors. The digestion buffer containing 0.3 mg/mL
Collagenase I type (Sigma-Aldrich, St. Louis, MO, USA) with PBS (Sigma-Aldrich, St. Louis, MO,
USA) was used per lung on an orbital shaker at 37 ◦C for 6 h. The cells suspension was gently mixed
using an 18-gauge needle, sequentially filtered through a 70 µm and 40 µm cell strainers (Falcon,
Becton Dickinson) into fresh tube and washed twice in PBS with the addition of 2% fetal bovine serum
(FBS, Sigma-Aldrich, St. Louis, MO, USA) by centrifugation at 900× g (4 min, 4 ◦C).
Magnetic sorting was performed using EasySep™Mouse Biotin Positive Selection Kit (Catalog
#18556, StemCell Technologies, Vancouver, BC, Canada) and Biotin Rat Anti-Mouse CD31 antibodies
(QC Testing: Mouse, Clone: MEC 13.3, Cat# 553371, 1/50 dilution, Becton Dickinson, San Jose, CA,
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USA). The fraction of CD31+ cells was isolated using EasySep™ Magnet (StemCell Technologies,
Vancouver, BC, Canada).
Assessment of the EasySep™ cell separation efficiency was carried out using flow cytometry as
described above.
4.9. Cultivation of CD31+ Lung Endothelial Cells with Treamid
The fraction of CD31+ cells (106 cells /1 mL of medium) obtained after magnetic sorting was
cultured on collagen-coated plastic plates for T-25 cell cultures in the medium M199 (Sigma-Aldrich,
St. Louis, MO, USA) consisted of 15% FBS (Sigma-Aldrich, St. Louis, MO, USA), 1 mM L-glutamine
(Sigma-Aldrich, St. Louis, MO, USA), 100 µg/mL heparin (Sigma-Aldrich, St. Louis, MO, USA) and
endothelial growth factor 50 µg/mL (Sigma-Aldrich, St. Louis, MO, USA) [47,50]. Cells were cultured
for five days in standard gas (3.5% CO2) and temperature conditions (37◦ C). The medium was changed
every one to two days.
After a five-day culture cycle, CD31+ cells of groups 1 and 2 were removed from the plate using
a warm 0.05% trypsin-EDTA solution (Sigma-Aldrich, St. Louis, MO, USA), changed to a medium
of the following composition: M199 with 15% FBS (Sigma-Aldrich, St. Louis, MO, USA), 1 mM
L-glutamine (Sigma-Aldrich, St. Louis, MO, USA), 100 µg/mL of heparin (Sigma-Aldrich, St. Louis,
MO, USA) and growth factor endothelium 50 µg/mL (Sigma-Aldrich, USA), and the cells were sown
at a concentration of 3 × 105 cells/1 mL of medium on collagen-coated plastic T-25 plates. Before
cultivation on the medium with CD31+ cells, we added Treamid (10−7 M). The cultivation cycle under
standard conditions (3.5% CO2, 37 ◦C) was 1 h. At the end of cultivation, the effectiveness of Treamid
on Carboxyfluorescein succinimidyl ester (CFSE) and apoptosis levels in CD31+ cell culture was
evaluated using image processing in each well of Cytation™ 3.
4.10. Lung Tissue Dissociation, Isolation and Magnetic Separation of CD326+ Lung Epithelial Cells
On the d21 we studied the effect of Treamid on CD326+ epithelial cells isolated from lungs of mice
from the control group (group 1) and mice with pulmonary fibrosis (group 2) in vitro. Lungs were
isolated from surrounding tissue, rinsed with PBS, mechanically dispersed, and minced with scissors.
We isolated lung cells as described above in Section 4.8. Lung epithelial cells were isolated using
protocol [51,52]. The single cells suspension was gently mixed using an 18-gauge needle, sequentially
filtered through a 70 µm cell strainer (Falcon, Becton Dickinson) and washed twice in PBS with the
addition of 2% FBS (Sigma-Aldrich, St. Louis, MO, USA) and 0,1% BSA (Sigma-Aldrich, St. Louis, MO,
USA) by centrifugation at 700× g (5 min, 4 ◦C).
Low-density cells were then isolated by density gradient centrifugation Histopaque-1077
(Sigma-Aldrich, St. Louis, MO, USA) in a 2:1 ratio (two suspensions per gradient) and then resuspended
and centrifuged for 20 min at room temperature at 1500 g. Harvest low-density cells from the interface
between the PBS layer and the Histopaque-1077 solution using a 10 mL pipet and transfer into a
50 mL centrifuge tube, washed twice in excess PBS supplemented with 0.1% BSA and 2% FBS 2% and
centrifuged for 5 min at 700× g and 4 ◦C. Counted the cells and calculated cell concentration.
The resulting cell suspension was subjected to magnetic sorting to enrich CD326+ cells. Magnetic
sorting was performed using EasySep™ Mouse Epithelial Cell Enrichment Kit II (Catalog # 19868,
Immunomagnetic negative selection kit, StemCell Technologies, Vancouver, BC, Canada) and CD326
(EpCAM) Antibody, anti-mouse, Biotin (QC Testing: Mouse, Clone: caa7-9G8, Cat# 130-118-075,
1/50 dilution, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany). Assessment of the
EasySep™ cell separation efficiency was carried out using flow cytometry as described above.
4.11. Cultivation of CD326+ Lung Epithelial Cells
Lung epithelial cells were cultured using as described in [51,52]. The fraction of CD326+
cells (106 cells /1 mL of medium) obtained by magnetic sorting was cultured on collagen-coated
plastic plates for T-25 cell cultures in 1:1 Hams F12: M199 (Sigma-Aldrich, USA) supplemented
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with 5% FBS (Sigma-Aldrich, St. Louis, MO, USA), 2 mM L-glutamine (Sigma-Aldrich, St. Louis,
MO, USA), 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA).
After 24 h, the medium was changed to serum-free medium composed of 1:1 Hams F12: M199
(Sigma-Aldrich, St. Louis, MO, USA), 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin,
100µg/mL insulin-transferrin-selenium (Sigma-Aldrich, St. Louis, MO, USA), 100 ng/mL hydrocortisone
(Sigma-Aldrich, USA), and 10 ng/mL epidermal growth factor (Sigma-Aldrich, St. Louis, MO, USA).
The medium was changed every one to two days. After a five-day culture cycle, CD326+ cells of groups
1 and 2 were detached from the plate using a warm 0.05% trypsin-EDTA solution (Sigma-Aldrich,
St. Louis, MO, USA) and the medium was changed to Hams F12:M199 (1:1) 5% FBS (Sigma-Aldrich,
St. Louis, MO, USA), 10 ng/mL epidermal growth factor (Sigma-Aldrich, St. Louis, MO, USA),
10 ng/mL basic fibroblast growth factor, 4 µg/mL heparin, 100 U/mL penicillin, 100 µg/mL streptomycin
(Sigma-Aldrich, St. Louis, MO, USA). Cells were plated at a concentration of 3 × 105 cells/1 mL on
collagen-coated plastic T-25 plates. Treamid was used at a concentration of 10−7 M). The effects of
Treamid on CD326+ cell culture were assessed by determining the levels of CFSE, CD49f, and apoptosis
levels using a Cytation 3 Cell Imaging multimode reader (BioTek Instruments, Inc., Winooski, VT, USA)
4.12. Cellular Imaging
Images of lung CD31+ endothelial and CD326+ epithelial cells were obtained using Cytation 3
equipped with DAPI, green fluorescent protein (GFP) and Texas Red light cubes.
At the end of the incubation period, lung endothelial and epithelial cells were stained with Hoechst
33342, CFSE BD Horizon, Annexin V-iFluor 350, and 7-AAD. In addition, a CD49f -FITC antibody was
used for the analysis of CD326+ epithelial cells. Images were taken on Cytation 3 (magnification of
4× or 20×) followed by cell analysis using Gen5™ data analysis software (Biotek, Bad Friedrichshall,
Germany).
All images were preprocessed to align the background before performing the analysis.
4.13. Statistical Analysis
Statistical analysis was performed using SPSS (version 15.0, SPSS Inc., Chicago, IL, USA). Data were
analyzed and presented as means± standard error of the mean. Statistical significance was evaluated by
Student’s t-test (for parametric data), or Mann–Whitney test (for nonparametric data) when appropriate.
A p-value of less than 0.05 (by two-tailed testing) was considered an indicator of statistical significance.
5. Conclusions
Our study provided evidence that Treamid has anti-inflammatory and antifibrotic effects and
induces lung tissue regeneration in animals with pulmonary fibrosis. The positive effect of treatment can
be explained by a decrease in inflammation, a rupture of the causal relationship between inflammation
and fibrosis, which reduces the activity of synthesis and deposition of collagen, and by a stimulation of
endothelial progenitor cells. Our results suggest that Treamid may be a promising therapeutic agent
for antifibrotic therapy and restoration of lung structure and function in IPF patients.
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Abbreviations
IPF Idiopathic pulmonary fibrosis
MSC Mesenchymal stem cells
BDDA Bisamide derivative of dicarboxylic acid or Treamid
BLM Bleomycin
Lm Mean linear intercept
DI Destructive index
PBS Phosphate buffered saline
FBS Fetal bovine serum
IL 13 Interleukin 13
CFSE Carboxyfluorescein succinimidyl ester
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